ClinicalTrials.gg
Active, not recruitingNCT05464784Updated Feb 5, 2026

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

A Phase 2 interventional study of MN-001 and MN-001 placebo in Diabetes Mellitus, Type 2, Hypertriglyceridemia and Non-Alcoholic Fatty Liver Disease, sponsored by MediciNova. Active, not recruiting at 2 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by MediciNova · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
2,034th of 2,961
40 · median 90
Started
2022
with 147 others
Phase 2
391 of 3,308
24 open now
Primary completion
2026-12
later than 144 of 477 live
Registered
2,682nd of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,034th largest by planned enrollment of the 2,961 interventional ones that give a count, is one of 148 that started in 2022, is one of 391 in phase 2, reaches primary completion later than 144 of the 477 other live ones, and was the 2,682nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The design of the Phase 2 clinical trial includes the following elements:

  • Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S.
  • Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks.
  • The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. FibroScan® is a non-invasive, quantitative, and accurate measure of liver fat content commonly used in early phase trials to measure treatment response.
  • Secondary endpoints include safety and tolerability and changes in lipid profile (HDL-C, LDL-C, and total cholesterol).
03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hypertriglyceridemia
  • Non-Alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • FibroScan® CAP score ≥ 248 dB/m within 8 weeks of randomization.
  • Diagnosis or history of Type 2 Diabetes mellitus with (HbA1c) >6.5 and ≤10% at Screening.
  • Fasting serum triglycerides (TG) at Screening >150 mg/dL
  • On a stable dose of oral antidiabetic therapy for a minimum of 3 months prior to Screening.

Exclusion criteria

Exclusion Criteria:

  • Other causes of chronic liver disease (, primary biliary cholangitis, , , Wilson's, α-1-antitrypsin deficiency, hemochromatosis, -proven cirrhosis, hepatocellular carcinoma);
  • Documented history of advanced liver fibrosis
  • Evidence of cirrhosis, hepatic decompensation, portal hypertension including splenomegaly, ascites, encephalopathy and/or esophageal varices;
  • Diagnosis or history of Diabetes mellitus type 1;
  • Weight change >5% within last 3 months of Screening visit;
  • Active gastrointestinal disease or history of gastric bypass surgery which could interfere with the absorption of oral medication;
  • History of acute cardiac event within 6 months of Screening;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    MN-001

    Drug: MN-001

  • Placebo comparator
    MN-001 Placebo

    The placebo comparator is a tablet identical in appearance to MN-001.

    Drug: MN-001 placebo

Interventions

  • DrugTipelukastStudies of TipelukastTipelukast pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MN-001 is a novel, orally bioavailable small molecule compound

  • DrugMN-001 placebo

    The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.

06

What researchers measure

Primary outcomes

  1. Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24

    Time frame: Week 24

  2. Mean change from baseline in fasting serum triglyceride levels at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Safety and tolerability of MN-001

    Incidence of adverse events, abnormal clinical laboratory results

    Time frame: Baseline to Week 24

  2. Mean change from baseline in lipids

    Changes in lipids (HDL-C, LDL-C, total cholesterol) after MN-001 treatment for 24 weeks

    Time frame: Baseline to Week 24

07

Study locations

2 sites
  • Jubilee Clinical Research, Inc.
    Las Vegas, Nevada 89106, United States
  • Pinnacle Clinical Research at South Texas Research Institute
    Edinburg, Texas 78539, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 52 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 19, 2022
StartActual
Aug 22, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05464784
Lead sponsor
MediciNova
Responsible party
Sponsor
First posted
Jul 19, 2022
Start date
Aug 22, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tipelukast

Start the discussion